Oura Expanded Wearable Features and Postponed I.P.O.
The wearable maker expanded health monitoring tools for international markets while delaying its public debut.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Do you trust wearable devices to accurately track your body's response to medication?
Oura has rolled out its GLP-1 Insights and Health Radar features to more than 30 new markets, including the European Union, Canada, and Australia. Simultaneously, the company postponed its planned Nasdaq listing, citing uncertainty in the initial public offering market.
Why it matters
The international rollout aims to capture demand from the projected 100 million global GLP-1 drug users by 2030. Meanwhile, the decision to pause its public offering highlights how broader market volatility can impact growth-stage capital strategies.
Oura reported $1.21 billion in revenue for the first nine months of 2026, a 74 percent increase compared to the prior year period, supporting a 5.7 million member base. The company previously sought a $14 billion valuation for its $2.2 billion Nasdaq offering.
The players
Oura
A Finland-based health technology company that manufactures smart rings and provides subscription-based health data services.
Anthropic
An artificial intelligence research and deployment company currently preparing for a planned public offering.
The details
The GLP-1 Insights feature integrates manual user logs regarding medication doses and side effects with automatic sensor data monitoring activity and sleep patterns. Additionally, Health Radar utilizes optical pulse signals to identify cardiovascular strain through blood pressure and breathing analysis. These tools are now available globally for Oura Ring Gen3 and later models.
Timeline
October 6, 2026: Oura announced the feature expansion and the delay of its I.P.O.
Q1-Q3 2026: Oura recorded 74 percent revenue growth.
November 15, 2026: Anthropic is scheduled to go public.
2030: 100 million people are expected to use GLP-1 drugs worldwide.
Market Landscape
The expansion of health-tracking software follows the rapid growth of GLP-1 medication adoption, which is projected to reach 100 million users by 2030. Oura's decision to pause its public offering also reflects a cautious approach to liquidity amid fluctuating market conditions.
Operators in the health and wellness space should monitor how integrated symptom-tracking tools influence user engagement and long-term retention. Businesses evaluating exit strategies should note that market volatility can force sudden pivots in capital-raising timelines.
The takeaway
The move to bundle medication-side-effect logging with biometric hardware signals a shift toward specialized, condition-specific wellness services. Owners should look to integrate similar automated data collection to increase the stickiness of their own digital health offerings.
Further reading
For more on industry shifts in medical technology, visit Healthcare.
Live Poll
Do you trust wearable devices to accurately track your body's response to medication?
